Cardiology Department, Clinica 'Villa Bianca', Bari, Italy.
Eur Heart J Acute Cardiovasc Care. 2012 Jun;1(2):158-69. doi: 10.1177/2048872612449111.
Recurrent angina in patients who underwent percutaneous coronary intervention is defined as recurrence of chest pain or chest discomfort. Careful assessment is recommended to differentiate between non-cardiac and cardiac causes. In the case of the latter, recurrent angina occurrence can be related to structural ('stretch pain', in-stent restenosis, in-stent thrombosis, incomplete revascularization, progression of coronary atherosclerosis) or functional (coronary micro-vascular dysfunction, epicardial coronary spasm) causes. Even though a complete diagnostic algorithm has not been validated, ECG exercise testing, stress imaging and invasive assessment of coronary blood flow and coronary vaso-motion (i.e. coronary flow reserve, provocation testing for coronary spasm) may be required. When repeated coronary revascularization is not indicated, therapeutic approaches should aim at targeting the underlying mechanism for the patient's symptoms using a variety of drugs currently available such as beta-blockers, calcium-channel blockers, ivabradine or ranolazine.
经皮冠状动脉介入治疗后患者的复发性心绞痛定义为胸痛或胸部不适的复发。建议进行仔细评估,以区分非心脏和心脏原因。在后一种情况下,复发性心绞痛的发生可能与结构性(“拉伸痛”、支架内再狭窄、支架内血栓形成、血管不完全再通、冠状动脉粥样硬化进展)或功能性(冠状动脉微血管功能障碍、心外膜冠状动脉痉挛)原因有关。尽管尚未验证完整的诊断算法,但可能需要进行心电图运动试验、应激成像以及冠状动脉血流和冠状动脉血管舒缩功能的有创评估(即冠状动脉血流储备、冠状动脉痉挛激发试验)。当不需要重复进行冠状动脉血运重建时,治疗方法应针对患者症状的潜在机制,使用目前可用的各种药物,如β受体阻滞剂、钙通道阻滞剂、伊伐布雷定或雷诺嗪。